Chimerix [CMRX] Unchanged to Buy at HC Wainwright & Co.
HC Wainwright & Co. maintained its Chimerix [CMRX] rating to the equivalent of Buy but changed the price target to $16.0 from $7, in a research note dated 2021-01-11. That figure represents around a 90.02% premium from where the company’s shares closed on Friday. Some new analysts also started their coverage, with H.C. Wainwright’s analysts […]
